# OnCo record rejuv-age-clonal-haematopoiesis-after-therapy (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-age-clonal-haematopoiesis-after-therapy/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-age-clonal-haematopoiesis-after-therapy" ;
  schema:name "Clonal haematopoiesis after cancer treatment"@en ;
  schema:description "Chemotherapy and radiotherapy do not select blood stem cells at random. They favour the ones carrying mutations in DNA-damage genes, which then expand. Most people with such a clone never develop a blood cancer, but the clone is a measurable mark of what treatment did, and in a minority it is the seed of a later leukaemia."@en ;
  schema:url <https://onco.cc/technologies/rejuv-age-clonal-haematopoiesis-after-therapy/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Clonal_hematopoiesis> ;
  schema:citation <https://doi.org/10.1016/j.stem.2017.07.010>, <https://doi.org/10.1038/s41588-020-00710-0> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "biological-ageing", "blood", "second-cancers" ;
  onco:related <https://onco.cc/technologies/rejuv-age-epigenetic-clocks/>, <https://onco.cc/technologies/rejuv-age-frailty-and-late-effects/>, <https://onco.cc/technologies/rejuv-frontier-what-works/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/terms/second-cancers-after-radiotherapy/> ;
  onco:pathways <https://onco.cc/pathways/clonal-haematopoiesis/> ;
  onco:terms <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/> .